JP2018532699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532699A5 JP2018532699A5 JP2018510734A JP2018510734A JP2018532699A5 JP 2018532699 A5 JP2018532699 A5 JP 2018532699A5 JP 2018510734 A JP2018510734 A JP 2018510734A JP 2018510734 A JP2018510734 A JP 2018510734A JP 2018532699 A5 JP2018532699 A5 JP 2018532699A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 130
- 102000036639 antigens Human genes 0.000 claims description 130
- 108091007433 antigens Proteins 0.000 claims description 130
- 239000012634 fragment Substances 0.000 claims description 130
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 123
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 119
- 238000000034 method Methods 0.000 claims description 93
- 229920001184 polypeptide Polymers 0.000 claims description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
- 238000010186 staining Methods 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 40
- 239000000523 sample Substances 0.000 claims description 38
- 239000013543 active substance Substances 0.000 claims description 34
- 238000001514 detection method Methods 0.000 claims description 30
- 238000003364 immunohistochemistry Methods 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 27
- 239000013074 reference sample Substances 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 14
- 238000002965 ELISA Methods 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 12
- 239000008188 pellet Substances 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 201000003444 follicular lymphoma Diseases 0.000 claims description 6
- 238000009007 Diagnostic Kit Methods 0.000 claims description 5
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 4
- 108090001008 Avidin Proteins 0.000 claims description 4
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 claims description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 4
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 4
- 102000048426 human CD37 Human genes 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000006249 magnetic particle Substances 0.000 claims description 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 4
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 238000003127 radioimmunoassay Methods 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 3
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 101710112752 Cytotoxin Proteins 0.000 claims description 2
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims description 2
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 102100031013 Transgelin Human genes 0.000 claims description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 230000001886 ciliary effect Effects 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 239000002619 cytotoxin Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 210000004880 lymph fluid Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000000638 mature B-cell neoplasm Diseases 0.000 claims description 2
- 208000010915 neoplasm of mature B-cells Diseases 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000004180 plasmocyte Anatomy 0.000 claims description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000003118 sandwich ELISA Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 230000003393 splenic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 229960005558 mertansine Drugs 0.000 description 1
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562211455P | 2015-08-28 | 2015-08-28 | |
| US62/211,455 | 2015-08-28 | ||
| US201562212183P | 2015-08-31 | 2015-08-31 | |
| US62/212,183 | 2015-08-31 | ||
| PCT/US2016/048887 WO2017040247A1 (en) | 2015-08-28 | 2016-08-26 | Antibodies and assays for detection of cd37 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532699A JP2018532699A (ja) | 2018-11-08 |
| JP2018532699A5 true JP2018532699A5 (enExample) | 2019-10-10 |
| JP6890581B2 JP6890581B2 (ja) | 2021-06-18 |
Family
ID=58188089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510734A Active JP6890581B2 (ja) | 2015-08-28 | 2016-08-26 | Ｃｄ３７の検出のための抗体およびアッセイ |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11104740B2 (enExample) |
| EP (1) | EP3341414A4 (enExample) |
| JP (1) | JP6890581B2 (enExample) |
| KR (1) | KR102766022B1 (enExample) |
| CN (1) | CN108699144B (enExample) |
| AU (1) | AU2016316758B2 (enExample) |
| CA (1) | CA2995243A1 (enExample) |
| EA (1) | EA201890347A1 (enExample) |
| HK (1) | HK1257199A1 (enExample) |
| IL (1) | IL257354B2 (enExample) |
| MA (1) | MA42706A (enExample) |
| MX (1) | MX2018002467A (enExample) |
| SA (1) | SA518391028B1 (enExample) |
| UA (1) | UA129489C2 (enExample) |
| WO (1) | WO2017040247A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201501803YA (en) | 2010-03-12 | 2015-05-28 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| EP2694105A4 (en) | 2011-04-01 | 2015-04-29 | Immunogen Inc | CD37 BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF |
| JP6979877B2 (ja) | 2015-06-08 | 2021-12-15 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ |
| CA2995243A1 (en) | 2015-08-28 | 2017-03-09 | Debiopharm International, S.A. | Antibodies and assays for detection of cd37 |
| JP2020510608A (ja) | 2016-11-02 | 2020-04-09 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７イムノコンジュゲート療法を改善するための方法 |
| JP2021525735A (ja) | 2018-05-30 | 2021-09-27 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７免疫コンジュゲート投薬レジメン |
| WO2020210643A1 (en) * | 2019-04-11 | 2020-10-15 | Ian Basil Shine | Cell membrane permeability restoring therapy |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5977316A (en) | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
| US20040166115A1 (en) | 2002-11-15 | 2004-08-26 | Immunomedics, Inc. | Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics |
| US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| EP1229934B1 (en) | 1999-10-01 | 2014-03-05 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| WO2002004021A1 (en) | 2000-07-12 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| KR20080087184A (ko) | 2001-01-31 | 2008-09-30 | 바이오겐 아이덱 인크. | 종양질환 치료를 위한 ｃｄ23 길항제의 용도 |
| US20030103971A1 (en) | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
| JP4463475B2 (ja) | 2001-01-31 | 2010-05-19 | バイオジェン アイデック インコーポレイテッド | 腫瘍疾患の治療における免疫調節性抗体の使用 |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US7786264B2 (en) | 2001-11-08 | 2010-08-31 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd | Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof |
| EP2022799A2 (en) | 2001-11-16 | 2009-02-11 | Biogen Idec Inc. | Polycistronic expression of antibodies |
| EP1572242B1 (en) | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| NZ543960A (en) | 2003-05-09 | 2008-11-28 | Univ Duke | CD20-specific antibodies and methods of employing same |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| US7241598B2 (en) * | 2004-06-29 | 2007-07-10 | The Chinese University Of Hong Kong | Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering |
| CA2572289A1 (en) * | 2004-06-30 | 2006-08-17 | Centocor, Inc. | Anti-mcp-1 antibodies, compositions, methods and uses |
| EP2311880A3 (en) | 2005-01-05 | 2011-07-27 | Biogen Idec MA Inc. | Cripto binding molecules |
| CA2597265C (en) | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| WO2006117910A1 (ja) * | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| CN101223448B (zh) | 2005-05-20 | 2012-01-18 | 健泰科生物技术公司 | 来自自身免疫病受试者的生物学样品的预处理 |
| WO2006133450A2 (en) | 2005-06-08 | 2006-12-14 | Duke University | Anti-cd19 antibody therapy for the transplantation |
| HUE026303T2 (hu) | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| HRP20140172T1 (hr) | 2006-05-30 | 2014-03-28 | Genentech, Inc. | Protutijela i imunokonjugati kao i njihove uporabe |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| CA2657763C (en) | 2006-08-03 | 2016-05-31 | Vaccinex Inc. | Anti-il-6 monoclonal antibodies and uses thereof |
| US7846434B2 (en) | 2006-10-24 | 2010-12-07 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
| CA2663536A1 (en) | 2006-10-24 | 2008-05-02 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
| PT2155783E (pt) | 2007-04-03 | 2013-11-07 | Amgen Res Munich Gmbh | Domínio de ligação específico inter-espécies |
| JP2010532764A (ja) | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド |
| PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| GB2454915B (en) | 2007-11-23 | 2012-02-15 | Schlumberger Holdings | Spooling apparatus for well intervention system |
| WO2009085573A2 (en) | 2007-12-28 | 2009-07-09 | Spring Bioscience Corporation | Quality control cell device for immunohistochemistry assay and methods of use thereof |
| AU2009234277B2 (en) | 2008-04-11 | 2014-12-04 | Aptevo Research And Development Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| US7740844B2 (en) * | 2008-04-29 | 2010-06-22 | Taiwan Liposome Co. Ltd | Anti-VEGF monoclonal antibody |
| CN102076717B (zh) | 2008-04-30 | 2016-02-03 | 伊缪诺金公司 | 交联剂和它们的用途 |
| NZ589880A (en) | 2008-06-16 | 2012-10-26 | Immunogen Inc | Use of synergistic anti-cancer compositions comprising lenalidomide, at least one corticosteroid and at least one immunoconjugate |
| MX2011000509A (es) | 2008-07-15 | 2011-04-05 | Genentech Inc | Conjugados derivados de antraciclina, proceso para su preparacion y su uso como compuestos antitumorales. |
| KR20110083730A (ko) | 2008-11-13 | 2011-07-20 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | Ｃｄ37 면역치료제 병용 요법 및 이의 용도 |
| JP2013506709A (ja) | 2009-10-06 | 2013-02-28 | イミュノジェン・インコーポレーテッド | 有効なコンジュゲートおよび親水性リンカー |
| EP2519544A1 (en) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
| US9175086B2 (en) | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| US9173961B2 (en) | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| SG10201501803YA (en) | 2010-03-12 | 2015-05-28 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| AU2011239583A1 (en) | 2010-04-15 | 2012-11-29 | Alper Biotech, Llc | Monoclonal antibodies against HER2 antigens, and uses therefor |
| ME03353B (me) * | 2011-03-29 | 2019-10-20 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
| EP2694105A4 (en) | 2011-04-01 | 2015-04-29 | Immunogen Inc | CD37 BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF |
| US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
| HK1203372A1 (en) * | 2011-12-13 | 2015-10-30 | Nordic Nanovector Asa | Chimeric therapeutic anti - cd37 antibodie hh1 |
| US20150093397A1 (en) * | 2012-03-30 | 2015-04-02 | Immunogen, Inc. | Methods for Increasing Efficacy of CD37-Based Therapy |
| WO2013171289A1 (en) | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with further agents |
| US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| PL2900277T3 (pl) | 2012-12-13 | 2022-05-16 | Immunomedics, Inc. | Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności |
| WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
| EP3332813B1 (en) | 2013-06-07 | 2019-05-29 | Nordic Nanovector ASA | Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| HK1222803A1 (zh) | 2013-11-07 | 2017-07-14 | 豪夫迈．罗氏有限公司 | 抗cd20抗体与btk抑制剂的组合疗法 |
| WO2015116729A2 (en) | 2014-01-28 | 2015-08-06 | Emergent Product Development Seattle, Llc | Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders |
| US20150343077A1 (en) | 2014-05-13 | 2015-12-03 | Immunogen, Inc. | Anti-CD37 Immunoconjugate Dosing Regimens |
| JP6979877B2 (ja) | 2015-06-08 | 2021-12-15 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ |
| CA2995243A1 (en) | 2015-08-28 | 2017-03-09 | Debiopharm International, S.A. | Antibodies and assays for detection of cd37 |
| JP2020510608A (ja) | 2016-11-02 | 2020-04-09 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７イムノコンジュゲート療法を改善するための方法 |
| JP2021525735A (ja) | 2018-05-30 | 2021-09-27 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７免疫コンジュゲート投薬レジメン |
-
2016
- 2016-08-26 CA CA2995243A patent/CA2995243A1/en active Pending
- 2016-08-26 KR KR1020187008906A patent/KR102766022B1/ko active Active
- 2016-08-26 MX MX2018002467A patent/MX2018002467A/es unknown
- 2016-08-26 MA MA042706A patent/MA42706A/fr unknown
- 2016-08-26 EA EA201890347A patent/EA201890347A1/ru unknown
- 2016-08-26 US US15/756,345 patent/US11104740B2/en active Active
- 2016-08-26 JP JP2018510734A patent/JP6890581B2/ja active Active
- 2016-08-26 CN CN201680047510.1A patent/CN108699144B/zh active Active
- 2016-08-26 WO PCT/US2016/048887 patent/WO2017040247A1/en not_active Ceased
- 2016-08-26 EP EP16842668.2A patent/EP3341414A4/en active Pending
- 2016-08-26 HK HK18116201.1A patent/HK1257199A1/zh unknown
- 2016-08-26 AU AU2016316758A patent/AU2016316758B2/en active Active
- 2016-08-26 UA UAA201801569A patent/UA129489C2/uk unknown
-
2018
- 2018-02-05 IL IL257354A patent/IL257354B2/en unknown
- 2018-02-27 SA SA518391028A patent/SA518391028B1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018532699A5 (enExample) | ||
| US11579142B2 (en) | Dosage regimen for administering a CD19xCD3 bispecific antibody to patients at risk for potential adverse effects | |
| JP6666905B2 (ja) | Ｐｄ−ｌ１抗体及びその使用 | |
| JP2015533788A5 (enExample) | ||
| CN109422811A (zh) | 抗cd47抗体及其用途 | |
| CN113330036B (zh) | 结合pd-l1和ox40的双特异性抗体 | |
| KR102416144B1 (ko) | 환자에서 항-cd19 치료법의 치료 이익의 예측 방법 | |
| US20190154701A1 (en) | Cytokine profiling analysis | |
| CN116997566A (zh) | 用PDGFRα抑制剂治疗癌症的方法 | |
| CN107430125B (zh) | 通过抑制tmcc3以抑制癌症的方法 | |
| AU2015207665A1 (en) | Cell surface prostate cancer antigen for diagnosis | |
| JP2020510608A (ja) | 抗ｃｄ３７イムノコンジュゲート療法を改善するための方法 | |
| JP2018059865A (ja) | 微小胞マーカーによる抗ｃｄ２０抗体医薬品に対する薬物感受性の予測方法 | |
| JP6977105B2 (ja) | Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用 | |
| JP2017120263A (ja) | 腫瘍由来の微小胞マーカーによる薬物感受性予測方法 | |
| WO2024206667A1 (en) | Detection of autoantibodies against nr1 | |
| JP7447255B2 (ja) | ヒト化抗ｃａ ｉｘ抗体、およびその使用方法 | |
| CN107709362B (zh) | Igf-1r抗体及其用于癌症诊断的用途 | |
| CN115516111A (zh) | 治疗癌症的方法 | |
| KR102172541B1 (ko) | Bag2 항체를 이용한 암 진단용 조성물 및 이를 이용한 방법 | |
| CN116940844A (zh) | 新颖生物标志物及其用途 | |
| Zorniak | Membrane proteomics of human glioblastoma stem-like cells | |
| CN120957750A (zh) | 用于治疗癌症的涉及grem1拮抗剂的组合疗法 | |
| HK40013319A (en) | Anti-cd47 antibody and use thereof | |
| CN110023762A (zh) | 用于预测利用抗vegf药物对渗出性年龄相关性黄斑变性进行的处置的有效性的方法 |